Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Inclusion Criteria:

• Participants with moderate-to-severe plaque psoriasis:

1. Deemed by the Investigator to be a candidate for phototherapy or systemictreatment for psoriasis, including ustekinumab;

2. Have at least 1 of the following cardiovascular risk factors:

• Current cigarette smoker

• Diagnosis of hypertension

• Diagnosis of hyperlipidemia

• Diabetes mellitus type 1 or 2

• History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heartattack), cardiac arrest, hospitalization for unstable angina, acute coronarysyndrome, stroke, or transient ischemic attack

• Obesity

• Family history of premature coronary heart disease or sudden death in a first-degreemale relative younger than 55 years of age or in a first-degree female relativeyounger than 65 years of age.

Exclusion Criteria:

• Participants must not have recent history of 1 of the following cardiovascularevents: MI, stroke, or coronary revascularization, or VTE within 90 days prior toDay 1.

• Participants must not have unstable CVD, defined as a recent clinical cardiovascularevent (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days prior to Day 1.

• Participants must not have evidence of active cancer or history of cancer (solidorgan or hematologic malignancy including myelodysplastic syndrome) orlymphoproliferative disease within the previous 5 years (other than resectedcutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ thathas been treated with no evidence of recurrence).

• Other protocol define inclusion/exclusion criteria apply.